Source: https://www.federalregister.gov/documents/2007/12/21/E7-24649/viruses-serums-toxins-and-analogous-products-standard-requirements-for-live-vaccines
Timestamp: 2018-04-19 22:19:15
Document Index: 79269830

Matched Legal Cases: ['art 113', 'art 113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113', '§\u2009113']

Federal Register :: Viruses, Serums, Toxins, and Analogous Products; Standard Requirements for Live Vaccines
Viruses, Serums, Toxins, and Analogous Products; Standard Requirements for Live Vaccines
A Rule by the Animal and Plant Health Inspection Service on 12/21/2007
72 FR 72563
72563-72564 (2 pages)
Docket No. APHIS-2006-0079
0579-AC30
E7-24649
List of Subjects in 9 CFR Part 113
https://www.federalregister.gov/d/E7-24649 https://www.federalregister.gov/d/E7-24649
Start Preamble Start Printed Page 72563
We are amending the Virus-Serum-Toxin Act regulations for certain live bacterial and viral vaccines by removing the requirement to retest the Master Seeds for immunogenicity 3 years after the initial qualifying immunogenicity test. In addition, we are amending the requirement concerning mouse safety tests prescribed for a biological product recommended for animals other than poultry. These changes update the standard requirements by eliminating unnecessary testing of Master Seed bacteria and viruses and other forms of bulk or completed biological product.
Effective Date: January 22, 2008.
Dr. Albert P. Morgan, Chief Staff Officer, Operational Support Section, Center for Veterinary Biologics, Policy, Evaluation, and Licensing, APHIS, USDA, 4700 River Road, Unit 148, Riverdale, MD 20737-1228; (301) 734-8245.
The Virus-Serum-Toxin Act regulations in 9 CFR part 113 (referred to below as the regulations) contain standard procedures and requirements that are used to establish the purity, safety, potency, and efficacy of veterinary biological products. Current standard requirements for certain live bacterial and viral vaccines require that each Master Seed be retested for immunogenicity 3 years after the initial immunogenicity test.
The requirement to confirm the immunogenicity of a Master Seed at 3 years has been in place since the master seed concept for vaccine production was established, and had been considered necessary until such time that an accumulation of data derived from such confirmatory testing established the antigenic stability of Master Seed bacteria and viruses over extended periods of storage. Data accumulated by veterinary biologics licensees over several years have shown that the immunogenicity of the Master Seed is not adversely affected over extended periods of storage.
On January 31, 2007, we published in the Federal Register (72 FR 4470-4472, Docket No. APHIS-2006-0079) a proposal[1] to amend the Virus-Serum-Toxin Act regulations for certain live bacterial and viral vaccines by removing the requirement to retest the Master Seeds for immunogenicity 3 years after the initial qualifying immunogenicity test. We also proposed to amend the requirement concerning mouse safety tests prescribed for biological products recommended for animals other than poultry.
We solicited comments concerning our proposal for 60 days ending April 2, 2007. We received two comments by that date, from a trade association representing veterinary biologics manufacturers and a representative of a State animal health commission.
One commenter supported the elimination of unnecessary testing/retesting from the regulations and noted that such action would decrease duplicative testing in animals. With regard to using the subcutaneous route of inoculation when conducting the mouse safety test, that same commenter recommended that proposed § 113.33(a)(1) should provide the option to split the injection volume among more than one injection site. The commenter pointed out that this recommendation was consistent with the “good practice” guidelines for subcutaneous injections recommended by the Association for Assessment and Accreditation of Laboratory Animal Care.
We agree with the commenter's recommendation and have amended § 113.33(a)(1) in this final rule to allow the option of dividing the 0.5 mL inoculation volume among more than one injection site.
The second commenter expressed concern that adverse local reactions may be missed if intraperitoneal inoculation is the only route used for the mouse safety test, and suggested that such test be conducted by inoculating mice using both the subcutaneous and intraperitoneal routes instead of by only one route as had been proposed.
In response to the commenter's concern that adverse local reactions may be missed if only one route is used, we wish to point out that § 113.300(b) of the regulations requires final container samples from each serial of product to be tested for safety in at least one species for which the vaccine is intended; the purpose of such test is to ensure freedom from undue adverse local reactions. Accordingly, we are not making any changes in this final rule in response to the comment.
We are amending the regulations for certain live bacterial and viral vaccines to eliminate the requirement to retest the Master Seed for immunogenicity 3 years after the initial qualifying immunogenicity test. In addition, this amendment updates the regulations concerning mouse safety tests by requiring either intraperitoneal or subcutaneous inoculation of mice, but not both, in such tests. The primary effect of this rule will be to update the standard requirements by eliminating unnecessary testing of Master Seed bacteria and viruses and other forms of bulk or completed product in animals. Start Printed Page 72564
There are approximately 125 veterinary biologics establishments, including licensees and permittees that may be affected by this rule. According to the standards of the Small Business Administration, most veterinary biologics establishments would be classified as small entities.
It is anticipated that no increased recordkeeping burden will be added to licensees or permittees since the amended regulations actually will mean that fewer tests will be needed and fewer reports required to be submitted. We further anticipate that licensees and permittees may benefit economically from the cost savings associated with the reduction in the amount of required animal testing. The overall effect of this amendment will be to reduce the costs associated with producing and testing veterinary biological products.
This final rule has been reviewed under Executive Order 12988, Civil Justice Reform. It is not intended to have retroactive effect. This rule will not preempt any State or local laws, regulations, or policies, unless they present an irreconcilable conflict with this rule. The Virus-Serum-Toxin Act does not provide administrative procedures which must be exhausted prior to a judicial challenge to the provisions of this rule.
This rule contains no new information or recordkeeping requirements under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.).
§ 113.8
2. In § 113.8, paragraph (d) is amended as follows:
a. In the heading by removing the words “
b. By removing paragraph (d)(1).
c. By removing the paragraph designation “(2)”.
3. In § 113.33, paragraphs (a)(1) and (a)(2) are revised to read as follows:
§ 113.33
Mouse safety tests.
(2) If unfavorable reactions attributable to the product occur in any of the mice during the observation period, the serial or subserial is unsatisfactory. If unfavorable reactions which are not attributable to the product occur, the test shall be declared inconclusive and may be repeated: Provided, That, if the test is not repeated, the serial or subserial shall be declared unsatisfactory.
§§ 113.66, 113.68, and 113.69
4. In §§ 113.66, 113.68, and 113.69, paragraph (b)(6) is removed and paragraph (b)(7) is redesignated as paragraph (b)(6).
5. In § 113.67, paragraph (b)(7) is removed and paragraph (b)(8) is redesignated as paragraph (b)(7).
§ 113.70
6. In § 113.70, paragraph (b)(5) is removed.
§§ 113.71, 113.306, and 113.318
7. In §§ 113.71, 113.306, and 113.318, paragraph (b)(4) is removed and paragraph (b)(5) is redesignated as paragraph (b)(4).
§ 113.303
8. In § 113.303, paragraph (c)(6) is removed.
§ 113.302, 113.304, 113.314, 113.315, 113.317, 113.327, 113.331, and 113.332
9. In §§ 113.302, 113.304, 113.314, 113.315, 113.317, 113.327, 113.331, and 113.332, paragraph (c)(4) is removed and paragraph (c)(5) is redesignated as paragraph (c)(4).
§ 113.305
10. In § 113.305, paragraphs (b)(1)(iii) and (b)(2)(iii) are removed and paragraph (b)(2)(iv) is redesignated as paragraph (b)(2)(iii).
§§ 113.308 and 113.316
11. In §§ 113.308 and 113.316, paragraph (b)(5) is removed and paragraph (b)(6) is redesignated as paragraph (b)(5).
§ 113.309
12. In § 113.309, paragraph (c)(9) is removed and paragraph (c)(10) is redesignated as paragraph (c)(9).
§ 113.310
13. In § 113.310, paragraph (c)(8) is removed and paragraph (c)(9) is redesignated as paragraph (c)(8).
§ 113.311
14. In § 113.311, paragraph (c)(7) is removed and paragraph (c)(8) is redesignated as paragraph (c)(7).
§ 113.312
15. In § 113.312, paragraphs (b)(5) and(b)(6) are removed and paragraph (b)(7) is redesignated as paragraph (b)(5).
§§ 113.313 and 113.328
16. In §§ 113.313 and 113.328, paragraph (c)(6) is removed and paragraph (c)(7) is redesignated as paragraph (c)(6).
§§ 113.325 and 113.326
17. In §§ 113.325 and 113.326, paragraph (c)(5) is removed and paragraph (c)(6) is redesignated as paragraph (c)(5).
§ 113.329
18. In § 113.329, paragraph (c)(5) is removed and paragraphs (c)(6) and (c)(7) are redesignated as paragraphs (c)(5) and (c)(6), respectively.
Done in Washington, DC, this 13th day of December 2007.
1. To view the proposed rule and the comments we received, go to http://www.regulations.gov/​fdmspublic/​component/​main?​main=​DocketDetail&​d=​APHIS-2006-0079.
[FR Doc. E7-24649 Filed 12-20-07; 8:45 am]